This approach could have particular significance in Brk-positive, triple negative breast cancers, as they are intrinsically less sensitive to conventional chemotherapy agents and current targeted therapies are of no benefit due to the negative receptor status of the tumours. The gene discussed is PTK6; the disease is triple-negative breast carcinoma.